| To Register SMDM Homepage | |
|
|
|
||||
| Monday, 18 October 2004: 7:00 AM-8:30 AM | |||
| Grand Ballroom 3 (Grand Hyatt Atlanta in Buckhead) | |||
| Poster Session - CEA: Methods and Applications; Health Services Research | |||
| 1 | A TIME-DEPENDENT MARKOV MODEL TO EVALUATE THE COST EFFECTIVENESS OF LOSARTAN IN TREATING PATIENTS WITH HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY Aslam H. Anis, PhD, Huiying Sun, PhD, Sonia Singh, MD, John C. Woolcott, MA, Bohdan Nosyk, MA | ||
| 2 | *ESTIMATING TRANSITIONS BETWEEN SYMPTOM SEVERITY STATES OF SCHIZOPHRENIC PATIENTS OVER TIME: A BAYESIAN META-ANALYTIC APPROACH Anirban Basu, PhD, (Candidate), Herbert Meltzer, MD, Vanja Dukic, PhD | ||
| 3 | IMPACT OF SECONDARY CARDIOVASCULAR EVENTS ON HEALTH STATUS Henk F. Van Stel, PhD, Jan J.V. Busschbach, PhD, M.G. Myriam Hunink, PhD, MD, Erik Buskens, PhD, MD | ||
| 4 | THE IMPACT OF FAILURE TO CALIBRATE ON RESULTS IN ECONOMIC EVALUATION Douglas Coyle | ||
| 5 | INDIVIDUAL PATIENT DATA META-ANALYSIS OF COST-EFFECTIVENESS RANDOMISED CONTROLLED TRIALS Brendan C Delaney, MD, Alex Ford, Michelle Qume, PhD, Paul Moayyedi, PhD | ||
| 6 | PROBABILISTIC ANALYSIS AND COMPUTATIONALLY EXPENSIVE MODELS: NECESSARY AND REQUIRED? Susan Griffin, MSc, BSc, Karl Claxton, PhD, Neil Hawkins, MSc, Mark Sculpher, PhD | ||
| 7 | BAYESIAN POSTERIOR DISTRIBUTIONS FOR PROBABILISTIC SENSITIVITY ANALYSIS Gordon B Hazen, PhD, Min Huang | ||
| 8 | *EMPIRICAL TEST AND VALIDATION OF THE WAITING-TRADEOFF (WTO) METHOD Thitima Kongnakorn, M.S., J. Shannon Swan, MD, Francois Sainfort, PhD | ||
| 9 | *MORBIDITY COST IN COST-EFFECTIVENESS ANALYSIS John A. Myers, PhD, Steven J. McCabe, MD, MSc, Stephan F. Gohmann, PhD | ||
| 10 | *A DECISION ANALYSIS OF PROSTATE CANCER WITH VARIABLE LEVELS OF DISEASE AGGRESSIVENESS E. Shannon Neeley, Scott B. Cantor, PhD, Dennis D. Cox, PhD | ||
| 11 | *PATIENT ADHERENCE: A BLIND SPOT IN COST-UTILITY ANALYSES? Allison B. Rosen, MD, ScD, Patricia W. Stone, PhD, Dan Greenberg, PhD, Peter J. Neumann, ScD | ||
| 12 | POTENTIAL COST EFFECTIVENESS OF AGGRESSIVELY TREATING MULTI-DRUG-EXPERIENCED HIV-POSITIVE PATIENTS Ahmed M. Bayoumi, MD, MSc, Gillian D. Sanders, PhD, Julie Munakata, MS, Douglas K. Owens, MD, MS | ||
| 13 | IS MOHS SURGERY A COST-EFFECTIVE TREATMENT FOR FACIAL NONMELANOMA SKIN CANCER? A DECISION ANALYSIS Tracy L. Bialy, M.D., MPH, Carl V. Washington, M.D, Herb Szeto, M.D, James Whalen, M.D, Suephy C Chen, MD, MS | ||
| 14 | BIOPSY OR RESECTION FOR SINGLE SMALL LIVER NODULES IN PATIENTS WITH COMPENSATED CIRRHOSIS- A DECISION ANALYSIS KE Bremner, BSc, AM Bayoumi, MD, MSc, M Sherman, MBBCH, PHd, M Krahn, MD, MSc | ||
| 15 | AGGRESSIVE LIPID LOWERING THERAPY IS A COST-EFFECTIVE INTERVENTION FOR SECONDARY PREVENTION IN POST-MYOCARDIAL INFARCTION PATIENTS Mehul Dalal, MD, MSc, Anita Karne, MD, MSc, Sundar Natarajan, MD | ||
| 16 | THE COST-EFFECTIVENESS OF TARGETED THERAPY FOR ADVANCED COLORECTAL CANCER Elena B. Elkin, PhD, Deborah Schrag, MD, MPH | ||
| 17 | *VALUE OF INFORMATION IN CAROTID REVASCULARISATION M P Janssen, E. Buskens | ||
| 18 | *A PROBABILISTIC COST-EFFECTIVENESS ANALYSIS OF ENOXAPARIN VS. UNFRACTIONATED HEPARIN FOR DVT PROPHYLAXIS FOLLOWING MAJOR TRAUMA Larry D. Lynd, PhD, Ron Goeree, MA, Bernie J. O'Brien, PhD | ||
| 19 | COST-EFFECTIVENESS ANALYSIS OF THROMBOLYTIC TREATMENT FOR STROKE Javier Mar, MD, Jose M Begiristain, MD, Arantza Arrazola, MD | ||
| 20 | *DECISION ANALYSIS FOR TUBERCULOSIS CONTROL USING A DYNAMIC EPIDEMIC MODEL Stephen Resch, MPH, Joshua Salomon, PhD, Megan Murray, MD, DPH, Milton C. Weinstein, PhD | ||
| 21 | IMPROVING PATIENT-TO-NURSE RATIOS AS A COST-EFFECTIVE SAFETY INTERVENTION Michael Rothberg, MD, MPH, Ivo Abraham, PhD, RN, Peter K Lindenauer, MD, David N Rose, MD | ||
| 22 | MEASUREMENT OF THE VALUE OF EXERCISE: A COST-EFFECTIVENESS ANALYSIS OF PROMOTING PHYSICAL ACTIVITY AMONG ADULTS L. Roux, MD, PhD, M. Pratt, MD, MPH, T. Yanagawa, MKin, M. Yore, MSPH, TO Tengs, ScD | ||
| 23 | COST EFFECTIVENESS OF THE IMPLANTABLE CARDIOVERTER DEFIBRILLATOR IN THE MADIT-II POPULATION Gillian D. Sanders, PhD, Mark A Hlatky, MD, Douglas K. Owens, MD, MS | ||
| 24 | *EVALUATION OF LONG-TERM CLINICAL EFFECTIVENESS AND COST-EFFECTIVENESS OF THE NEW GENOTYPE-SPECIFIC GUIDELINES FOR CHRONIC HEPATITIS C TREATMENT IN GERMANY Uwe Siebert, MD, MPH, MSc, Gaby Sroczynski, MPH, Pamela Aidelsburger, MD, MPH, Siegbert Rossol, MD, Jürgen Wasem, PhD, Michael P. Manns, PhD, MD, John G. McHutchison, MD, John B. Wong, MD, FACP | ||
| 25 | PRACTICAL USE OF COST-EFFECTIVENESS FOR COMMUNITY PLANNING OF HIV PREVENTION Shin-Yi Wu, Ph.D., Deborah Cohen, MD, MPH, Thomas A. Farley, MD, MPH | ||
| 26 | *PROPENSITY SCORING: A COMPARISON OF GREEDY VS. OPTIMAL MATCHING TECHNIQUES Shibani Mahajan, MPH, Kevin J. Anstrom, PhD, Teresa L. Kauf, PhD, Kevin A. Schulman, MD | ||
| 27 | *ARE RELATIONSHIPS BETWEEN SF-36 SUBSCALES AND HEALTH UTILITY MERELY LINEAR? Andrew P. Yu, MA, MS, Yanni F. Yu, MA, Michael B Nichol, PhD | ||
| 28 | CAN MELANOMA PATIENTS PREDICT THE QUALITY OF LIFE IMPACT OF AN ALTERNATE MELANOMA STAGE? SE Bendeck, MD, JC Hadley, BA, P Bonaccorsi, MD, KM Brown, MD, DH Lawson, MD, DR Murray, MD, CV Washington, MD, SC Chen, MD, MS | ||
| 29 | DEFINING EPISODIC COSTS OF INJURIES: THE CASE OF SUICIDE ATTEMPTS Phaedra Corso, PhD, MPA, Tadesse Haileyesus, MS | ||
| 30 | PREDICTORS OF USE OF HANDHELD DECISION SUPPORT TOOLS IN THE CLINICAL SETTING Feliciano B. Yu, MD, MSHI, Thomas K. Houston, MD, MPH, Midge N. Ray, RN, MSN, Eta S. Berner, Ed.D. | ||
| 31 | OUTCOMES OF A MULTIDISCIPLINARY PHYSICIAN-LED PRACTICE MANAGEMENT INTERVENTION TO CONTROL COSTS DURING AN ERA OF RAPID TECHNOLOGIC EVOLUTION IN CORONARY INTERVENTIONS Celia C Kamath, PhD, Charanjit S. Rihal, M.D., Kathy Reller, RN, Stephanie S Anderson, MA, Erin K. McMurtry, B.S., John F. Bresnahan, M.D., David R. Holmes, M.D., Kirsten Hall Long, Ph.D. | ||
| 32 | *RACIAL DISPARITIES IN THE PRESCRIBING OF WARFARIN FOR NONVALVULAR ATRIAL FIBRILLATION Daniel P. Schauer, MD, Joseph A. Johnston, MD, MSc, Mark Wess, MD, Charles Moomaw, PhD, Mark Eckman, MD, MS | ||
| 33 | ROSUVASTATIN: SUPER-STATIN OR ALSO-RAN? A MULTI-CRITERIA DECISION ANALYSIS OF THE IMPACT OF ROSUVASTATIN ON OPTIMAL CLINICAL USE OF STATINS James G. Dolan, MD | ||
| 34 | PROVIDER ADHERENCE WITH QUALITY IMPROVEMENT STRATEGIES FOR MANAGEMENT OF HYPERTENSION: A SYSTEMATIC REVIEW Judith Walsh, MD, MPH, Kathryn M. McDonald, MM, Kaveh G. Shojania, MD, Vandana Sundaram, MPH, Robyn Lewis, MA, Smita Nayak, MD, Jody Mechanic, RN, Douglas K. Owens, MD, MS, Mary K. Goldstein, MD | ||
| 35 | TARGETING FRAGILITY FRACTURES IN AN ORTHOPAEDIC TREATMENT UNIT: COSTEFFECTIVENESS OF A DEDICATED COORDINATOR Beate Sander, RN, MEcDev, Andreas Maetzel, MD, PhD, Victoria Elliot-Gibson, MSc, Dorcas E. Beaton, PhD, Earl R. Bogoch, MD | ||
| 36 | FACTORS AFFECTING RESPONSE TO AND COMPLETION OF PHYSICIAN SURVEYS Jamie Brehaut, PhD, Ian Graham, PhD, Laura Visentin, BSc, Ian Stiell, MD | ||
See more of The 26th Annual Meeting of the Society for Medical Decision Making (October 17-20, 2004)
Papers submitted for the Lee B. Lusted Student Prize Competition are denoted with an asterisk (*)